Category: CovidienSyndicate content

Masimo throws down the gauntlet with $1M challenge against Covidien

May 31, 2013 by Arezu Sarvestani

Masimo offers $1 million to any hospital that proves that its Masimo SET pulse oximeters are less accurate that Covidien's Nellcor devices.

arm wrestling

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

FDA clears Covidien's Nellcor pulse oximeter for pediatric care

May 28, 2013 by Sony Salzman

The FDA clears Covidien's Nellcor pulse oximeter for diagnosing congenital heart disease in infants.

Covidien

Covidien (NYSE:COV) landed a 510(k) for its Nellcor pulse oximeter, which the federal watchdog agency OK'd for diagnosis of infant critical congenital heart disease (CCHD).

The Mansfield, Mass.-based med-tech titan already sells other devices in the Nellcor patient monitoring line, and is touting the pulse oximeter as the first ISO 8601-2-61 compliant oximeter in the U.S. market.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

The bulls may have run a little too far with St. Jude Medical

May 27, 2013 by MassDevice

MassDevice.com columnist Stephen Simpson on St. Jude Medical's stock activity, as shares have hit the mid-$40s in recent weeks.

St. Jude Medical logo

By Stephen Simpson

Covidien launches its new respiratory monitoring device

May 23, 2013 by Sony Salzman

Covidien's MicroStream MicroPod respiratory monitoring module hits the shelves

Covidien (NYSE:COV) launched its Microstream MicroPod respiratory monitoring module in the U.S, which measures carbon dioxide levels to determine changes that can lead to breathing problems.

The product is integrated with other patient monitoring systems already on the market for Covidien's Original Equiptment Manufacturer partners.

Covidien touts positive study data from Barrx ablation system

May 22, 2013 by Sony Salzman

Covidien champions positive results for the Barrett's esophagus ablation device it acquired along with Barrx in 2011.

Covidien touts positive study data from Barrx ablation system

Covidien (NYSE:COV) touted study results showing that the Barrett's esophagus treatment it acquired along with Barrx 2 years ago reduces pre-cancerous tissue.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Chest docs include Covidien's superDimension lung biopsy device in guidelines

May 21, 2013 by Sony Salzman

The lung biopsy device acquired by Covidien in its superDimension acquisition is included in new guidelines from the American College of Chest Physicians.

Covidien

Covidien (NYSE:COV) said the lung biopsy device it acquired along with superDimension last year was included in new guidelines from the American College of Chest Physicians.

The superDimension electromagnetic navigation bronchoscopy system is designed to use the lungs own airways to obtain biopsies of suspect tissue earlier than other treatment options.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Covidien restates Q2 financials ahead of pharma spinout | Wall Street Beat

May 20, 2013 by Brad Perriello

Covidien restates its financial results for its fiscal 2nd quarter ahead of the spinout of its Mallinckrodt pharmaceuticals business, expected next month.

MassDevice.com Wall Street Beat

Covidien (NYSE:COV) re-stated its financial results for the fiscal 3rd quarter ended March 29, in anticipation of the planned spinout of its Mallinckrodt pharmaceuticals business next month.

Covidien said the new numbers reflect the pharma unit as a discontinued operation, with COV shareholders slated to receive a tax-free distribution, according to a regulatory filing.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.